Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Mitchell SR, et al. Among authors: baloglu e. Blood Adv. 2019 Feb 12;3(3):242-255. doi: 10.1182/bloodadvances.2018024182. Blood Adv. 2019. PMID: 30692102 Free PMC article.
Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT, Baloglu E, Landesman Y. Senapedis WT, et al. Among authors: baloglu e. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Semin Cancer Biol. 2014. PMID: 24755012 Review.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Gravina GL, et al. Among authors: baloglu e. J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. J Hematol Oncol. 2014. PMID: 25476752 Free PMC article. Review.
Therapeutic Potential of Targeting PAK Signaling.
Senapedis W, Crochiere M, Baloglu E, Landesman Y. Senapedis W, et al. Among authors: baloglu e. Anticancer Agents Med Chem. 2016;16(1):75-88. doi: 10.2174/1871520615666150617111414. Anticancer Agents Med Chem. 2016. PMID: 26081410 Review.
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, Tyner JW, Wang MR, Koeffler HP. Jiang YY, et al. Among authors: baloglu e. Gut. 2017 Aug;66(8):1358-1368. doi: 10.1136/gutjnl-2016-311818. Epub 2016 May 10. Gut. 2017. PMID: 27196599 Free PMC article.
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. Etchin J, et al. Among authors: baloglu e. Leukemia. 2017 Jan;31(1):143-150. doi: 10.1038/leu.2016.145. Epub 2016 May 23. Leukemia. 2017. PMID: 27211268 Free PMC article.
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R. Hing ZA, et al. Among authors: baloglu e. Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20. Leukemia. 2016. PMID: 27323910 Free PMC article.
99 results